(BOSTON, USA) – CARB-X is awarding up to US$3.83 million to The University of Queensland’s Institute for Molecular Bioscience, Brisbane, Australia, to develop a new class of antibiotics to treat serious drug-resistant bacterial infections. The Institute will be eligible for an additional $7.03 million if the project meets certain development milestones, for a total award of up to $10.86 million.
The University of Queensland’s project aims to identify Octapeptin cyclic peptides that maintain their antibacterial potency against polymyxin-resistant Gram-negative pathogens, but have fewer side effects. The goal is to develop a safer antibiotic to replace last-resort polymyxin class antibiotics, such as colistin, that are used to treat life-threatening drug-resistant infections for which no other antibiotics will work. Last-resort polymyxin class antibiotics can cause severe kidney and neurological side effects.
Click link for Full Story: CARB-X funds University of Queensland
The AMR Centre has combined forces to attract much needed investment to combat the global threat of antimicrobial resistance (AMR) resulting in a successful bid for a £114 million project supported by UK Research and Innovation (UKRI). The funding was secured by a North West UK based consortium that will work in partnership to create an integrated platform for the development of new treatments and diagnostics for infectious diseases.
Click link for full story: AMR Centre funding
This Center is hosted by Milken Institute School of Public Health, George Washington University, USA.
“Our central mission is to bring together epidemiologists, microbiologists, communications experts, policy experts, together under a single roof, working day in and day out, to curb these superbugs and to protect antibiotics.”
Click link: ARAC
This is a new website, hosted by the Milken Institute School of Public Health, George Washington University, USA, to educate the General Public on Antibiotic Resistance.
Clink link: Antibiotics and You
This research report (Feb 2020) offers a snapshot of the threat that rising antibiotic resistance poses to the treatment of cancer. The results of the study shine a light on UK’s oncologists worries about the rise of antibiotic resistance and what it means, in their eyes, for the effective care of their patients. It serves a dual purpose: raising awareness of the risks posed by superbugs to healthcare as we know it, and, we hope, encouraging increased support for R&D and procurement for both antibiotics and rapid-diagnostics.
Click link for report: Report
In 2019, The Economist held its inaugural Antimicrobial Resistance Summit in London and Singapore. Bringing together policymakers, pharmaceutical companies, academic researchers and NGOs, the event made a compelling case for increasing both financial investment and policy attention to antimicrobial resistance (AMR), to avoid a future public health crisis.
The event presented a balance of optimism and concern; both events were forward-looking and looked at positive success stories and innovations, including public education campaigns, improvements in diagnostic technologies, data collaboration, and academic partnerships to combat AMR.
Speakers praised concrete action plans, while also noting a large number of countries without an AMR strategy. The contribution of the private sector also attracted both praise and scrutiny. Excessive marketing practices have encouraged irrational antibiotic usage, too many large pharmaceutical companies lack an AMR position, and the food and environment industries need to be more engaged given the interlinkages of AMR. At the same time, the private sector is a source of ideas and investment, from developing the rapid diagnostic technologies needed to reduce unnecessary antibiotic use, to developing new paradigms such as inhibiting bacterial functions, rather than focus only on elimination. Pharmaceutical companies, for their part, also called for greater support in cracking down on substandard counterfeit medicines, and for ‘push’ and ‘pull’ policy stimulus measures given the challenging economics of antibiotic research.
Click Link: Summit Details
Signs of progress against the superbugs, but not yet at the scale needed
The 2020 Antimicrobial Resistance Benchmark evaluates how 30 pharmaceutical companies are limiting drug-resistance.
Amsterdam, the Netherlands, 21 January 2020 – A core group of pharmaceutical companies are making progress in tackling the spread of antimicrobial resistance, new findings from the 2020 Antimicrobial Resistance Benchmark indicate. However, although a few companies are expanding their efforts, change is not happening at the scale needed to radically impact the threat from drug resistance.
Click link: Report summary
Just published in the Lancet
Sepsis is life-threatening organ dysfunction due to a dysregulated host response to infection. It is considered a major cause of health loss, but data for the global burden of sepsis are limited. As a syndrome caused by underlying infection, sepsis is not part of standard Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) estimates. Accurate estimates are important to inform and monitor health policy interventions, allocation of resources, and clinical treatment initiatives. We estimated the global, regional, and national incidence of sepsis and mortality from this disorder using data from GBD 2017.
Click Link: Full Report
AMR Industry Alliance reports breakthroughs in the responsible manufacturing of antibiotics and positive steps to improve how patients access and use antibiotics. But its report also highlights concerning levels of research and development (R&D) investment.
Click Link for Details: Report
The 6th World One Health Congress takes place in Edinburgh, Scotland on 14th-18th June 2020.
Click link: Congress Link